The discounted cash flow (DCF) for the valuation of IDSB would be completely different now. IOU could write down the value of IDSB for what they paid but it's not going to be valued at that amount if they were to sell it on. It's an asset that yields 2.5%. The 2.5% is counted as income for the business. That's all you can really look at imo.
If IOU were to issue shares to raise capital I wouldn't be paying anymore than 5c per share with current operations.
Think of it this way, they had $58m a year or so ago. They have invested all of it into building the business and out of that they have been able to produce $5.8m in revenue this quarter or say $23m per year. It's not a terrible result however there business has hit a roadblock as it's run out of money. If the company raises another $10m-$15m, double digital transactions and secured a funding facility then the valuation changes. Without any cash the value shrinks.
This is my opinion, no one has to agree with me.
- Forums
- ASX - By Stock
- Ann: March Quarterly Activities Report
The discounted cash flow (DCF) for the valuation of IDSB would...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OVT (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.4¢ |
Change
-0.007(17.1%) |
Mkt cap ! $73.08M |
Open | High | Low | Value | Volume |
4.3¢ | 4.4¢ | 3.1¢ | $5.944M | 163.2M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 1930772 | 3.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.4¢ | 4335524 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 1930772 | 0.033 |
20 | 3663191 | 0.032 |
23 | 7648005 | 0.031 |
29 | 3193168 | 0.030 |
12 | 2405931 | 0.029 |
Price($) | Vol. | No. |
---|---|---|
0.034 | 4335524 | 13 |
0.035 | 4241048 | 10 |
0.036 | 3582895 | 11 |
0.037 | 10337468 | 10 |
0.038 | 4630038 | 14 |
Last trade - 13.31pm 13/11/2024 (20 minute delay) ? |
Featured News
OVT (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online